5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 32026-10-06NCT07284901
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 32026-10-06NCT07284875
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration; nAMDRecruitingPhase 32026-09-29NCT07614776
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisActive, not recruitingPhase 32026-06-02NCT06550076
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorderActive, not recruitingPhase 32026-04-13NCT06846541